The FDA authorized the first fully autonomous robotic blood-draw device
Vitestro's Aletta performs a complete venipuncture, tourniquet through bandage, without a human operator, and the agency's own authorization lets one phlebotomist supervise up to three devices at once.
The FDA announced on August 19, 2026 that it had authorized Vitestro's Aletta system through the De Novo pathway -- the route the agency uses for a new type of low- to moderate-risk device, one with no existing predicate to compare it against. Aletta is built to perform a full venipuncture blood draw on its own: it uses near-infrared light and Doppler ultrasound to locate a vein, then independently applies the tourniquet, disinfects the skin, inserts the needle, collects the sample, and applies the bandage, without a person doing any of those individual steps.
What the authorization allows
A trained phlebotomist still starts each session and watches for complications, but doesn't perform the draw -- and per the FDA's own announcement, that supervision ratio doesn't have to be one-to-one: a single phlebotomist can oversee up to three Aletta devices running at the same time. Alongside the authorization, the FDA established special controls specific to this new device category, covering labeling, performance testing, and clinical requirements, which future robotic blood-draw devices from other manufacturers will also have to meet. CDRH director Michelle Tarver framed the decision as balancing capability against risk: the authorization, in her words, "advanc[es] innovative medical devices that help meet a critical public health need."
Why the staffing ratio is the number that matters
The headline capability here, a robot doing a needle stick unsupervised, gets the attention, but the one-to-three staffing ratio is the number with a balance sheet attached to it. A hospital lab or blood-draw clinic evaluating this is buying more than a device that performs a task: it's buying a claimed change in how many trained staff a given volume of draws requires, and that claim needs to be measured against real throughput and error rates in a live clinical setting, not taken as validated the moment a De Novo authorization letter is signed. The FDA's special controls give a published bar those follow-on measurements can be checked against. Most AI-adjacent product launches offer less, and this is a fair model for what a credible autonomy claim in a regulated industry looks like.